NEW YORK (AP) -- India-based Lupin Pharmaceuticals Inc. said Thursday it received Food and Drug Administration approval for a generic version of Merck & Co.'s oral suspension version of the heartburn drug Pepcid.
Pepcid for oral suspension had annual sales of about $29 million for the 12 months ended in March 2010, Lupin said.
